Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y
Bone Marrow Transplant. 2024; 59(6):717-741.
PMID: 38413823
PMC: 11809468.
DOI: 10.1038/s41409-023-02190-2.
Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y
Transplant Cell Ther. 2024; 30(4):349-385.
PMID: 38413247
PMC: 11181337.
DOI: 10.1016/j.jtct.2023.12.001.
Kirsch J, Hogan W, Patnaik M, Ehlers S
Bone Marrow Transplant. 2023; 58(5):581-583.
PMID: 36693926
DOI: 10.1038/s41409-023-01921-9.
Fitzhugh C, Volanakis E, Idassi O, Duberman J, DeBaun M, Friedman D
J Clin Med. 2022; 11(11).
PMID: 35683502
PMC: 9181610.
DOI: 10.3390/jcm11113118.
Leppla L, Schmid A, Valenta S, Mielke J, Beckmann S, Ribaut J
Support Care Cancer. 2021; 29(12):8045-8057.
PMID: 34224016
PMC: 8550349.
DOI: 10.1007/s00520-021-06328-0.
Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.
Chakraborty R, Hill B, Majeed A, Majhail N
Transplant Cell Ther. 2021; 27(3):222-229.
PMID: 33928266
PMC: 8078596.
DOI: 10.1016/j.jtct.2020.10.002.
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.
Kahn J, Brazauskas R, Tecca H, Bo-Subait S, Buchbinder D, Battiwala M
Blood Adv. 2020; 4(9):2084-2094.
PMID: 32396620
PMC: 7218429.
DOI: 10.1182/bloodadvances.2019000839.
Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation.
Mani S, Khera N, Rybicki L, Marneni N, Carraway H, Moore H
Clin Lymphoma Myeloma Leuk. 2019; 20(2):70-77.
PMID: 31810888
PMC: 7023983.
DOI: 10.1016/j.clml.2019.11.008.
Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplantation Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.
Morken C, Tevaarwerk A, Swiecichowski A, Haine J, Williams Z, Norslien K
Biol Blood Marrow Transplant. 2019; 25(6):1240-1246.
PMID: 30763727
PMC: 6559830.
DOI: 10.1016/j.bbmt.2019.02.003.
Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors.
Majhail N, Murphy E, Laud P, Preussler J, Denzen E, Abetti B
Haematologica. 2018; 104(5):1084-1092.
PMID: 30514795
PMC: 6518896.
DOI: 10.3324/haematol.2018.203919.
Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities.
Shah G, Majhail N, Khera N, Giralt S
Curr Hematol Malig Rep. 2018; 13(2):125-134.
PMID: 29484578
PMC: 6686881.
DOI: 10.1007/s11899-018-0444-z.
Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation.
Burns L, Abbetti B, Arnold S, Bender J, Doughtie S, El-Jawahiri A
Biol Blood Marrow Transplant. 2018; 24(6):1111-1118.
PMID: 29408289
PMC: 5993588.
DOI: 10.1016/j.bbmt.2018.01.029.
Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
Myers R, Hill B, Shaw B, Kim S, Millard H, Battiwalla M
Cancer. 2017; 124(4):816-825.
PMID: 29125192
PMC: 5871233.
DOI: 10.1002/cncr.31114.
Long-term complications after hematopoietic cell transplantation.
Majhail N
Hematol Oncol Stem Cell Ther. 2017; 10(4):220-227.
PMID: 28641097
PMC: 5925745.
DOI: 10.1016/j.hemonc.2017.05.009.
Coordination of Care in Survivorship After Treatment of Hematological Malignancies-The Journey is Not Over Yet.
Lee C, Muffly L
Curr Hematol Malig Rep. 2017; 12(4):317-323.
PMID: 28534144
DOI: 10.1007/s11899-017-0390-1.
Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
Preussler J, Meyer C, Mau L, Majhail N, Denzen E, Edsall K
Biol Blood Marrow Transplant. 2017; 23(6):1021-1028.
PMID: 28263920
PMC: 5497312.
DOI: 10.1016/j.bbmt.2017.02.017.
Late effects of blood and marrow transplantation.
Inamoto Y, Lee S
Haematologica. 2017; 102(4):614-625.
PMID: 28232372
PMC: 5395102.
DOI: 10.3324/haematol.2016.150250.
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes.
Battiwalla M, Hashmi S, Majhail N, Pavletic S, Savani B, Shelburne N
Biol Blood Marrow Transplant. 2016; 23(1):6-9.
PMID: 27989931
PMC: 5182086.
DOI: 10.1016/j.bbmt.2016.10.020.
Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care.
Battiwalla M, Tichelli A, Majhail N
Biol Blood Marrow Transplant. 2016; 23(2):184-192.
PMID: 27818318
PMC: 5237604.
DOI: 10.1016/j.bbmt.2016.11.004.